Jaguar Health’s stock slammed after drug that aims to reduce gastro issues in cancer patients fails to meet trial goals
Jaguar Health Inc.’s stock tumbled 66% Tuesday, after the biotech said a late-stage trial of a drug that aims to prevent diarrhoea in cancer patients undergoing treatment failed to meet its main goal across all tumor types.